References
- David NJ. Noble J David, MD, reminisces. J Neuroophthalmol 2002;22:240–246.
- Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol 2010;23:145–153.
- Riches JC, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol 2010;20:431–438.
- Nunes C, Wong R, Mason M, et al. Expansion of a CD8(+)PD–1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 2012;18:678–687.
- Lim MY, Fedoriw Y, Ramanayake H, et al. Epstein-Barr virus reactivation and hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 2014;55:2938–2941.
- Machaczka M, Vaktnas J, Klimkowska M, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma 2011;52:613–619.
- Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–131.
- Kilari D, Venci N, Friedberg J, et al. Hemophagocytic lympho- histiocytosis masquerading as progressive chronic lymphocytic leukemia. Leuk Res Rep 2013;2:4–6.
- Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013;122:2539–2549.
- Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32–42.